This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Qiagen (QGEN) Q4 Earnings Lag Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of -1.61% and 0.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
by Zacks Equity Research
Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
by Zacks Equity Research
BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
by Zacks Equity Research
Pacira stock gains 11% on better-than-expected preliminary Q4 sales figures. It also shares a strategic growth plan to drive innovation and value creation by 2030.
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
by Zacks Equity Research
Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
by Zacks Equity Research
Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
by Zacks Equity Research
Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
by Zacks Equity Research
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Halozyme (HALO) stock based on the movements in the options market lately.
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief
by Zacks Equity Research
Pacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like the medial branch nerve.
Here's Why You Should Consider Buying Atara Biotherapeutics Stock
by Zacks Equity Research
Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
by Zacks Equity Research
Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.
Geron Stock Rallies More Than 60% in a Year: Here's Why
by Zacks Equity Research
FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
Here's Why Investors Should Retain Molina Healthcare Stock for Now
by Zacks Equity Research
MOH remains well-poised for growth, attributable to improved premium revenues, buyouts and an aging U.S. population.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.